Holen Sie sich die Stockscreener-App
1.88
1.08%
0.02
Schlusskurs vom Vortag:
$1.86
Offen:
$1.92
24-Stunden-Volumen:
785.60K
Relative Volume:
0.99
Marktkapitalisierung:
$200.06M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.64M
KGV:
-4.4487
EPS:
-0.4226
Netto-Cashflow:
$-13.98M
1W Leistung:
-11.32%
1M Leistung:
+8.67%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.80
$1.94
1-Wochen-Bereich:
$1.80
$2.16
52-Wochen-Spanne:
$1.70
$5.9299
Nervgen Pharma Corp Stock (NGEN) Company Profile
Firmenname
Nervgen Pharma Corp
Sektor
Branche
Telefon
-
Adresse
-
Compare NGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NGEN
Nervgen Pharma Corp
|
1.88 | 200.06M | 0 | -31.64M | -13.98M | -0.4226 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nervgen Pharma Corp Stock (NGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Eingeleitet | H.C. Wainwright | Buy |
Nervgen Pharma Corp Aktie (NGEN) Neueste Nachrichten
Lobbying Update: $50,000 of NERVGEN PHARMA CORP. lobbying was just disclosed - Quiver Quantitative
If You Invested $1,000 in Nervgen Pharma Corp (NGENF) - Stock Titan
NGEN Q3 2025 Earnings: Narrow EPS Beat Masks Continued Pre-Revenue Stage, Stock Sheds Nearly 7%EPS Consistency Score - dars.gov.et
Breakthrough peptide repairs nerves after spinal cord injury in clinical trial - BioXconomy
NervGen Pharma (NGEN) Q3 2025 Earnings: Small EPS Beat Amid Ongoing Clinical Development and Cash ManagementEarnings Growth Analysis - dars.gov.et
NervGen Pharma(NGEN) Stock Options Chain | Quotes & News - Moomoo
NervGen Pharma remains a Buy after FDA aligns o... - Pluang
NervGen Pharma: I Think The Biggest Risks Are Now Behind It (NASDAQ:NGEN) - Seeking Alpha
Enterprise value to revenue forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
Price to book forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
Price to sales forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
NervGen Pharma Corp. Actuals & Estimates (NASDAQ:NGEN) - TradingView
NGEN Forecast — Price Target — Prediction for 2027 - TradingView
9UA Forecast — Price Target — Prediction for 2027 - TradingView
NervGen Pharma Corp. Actuals & Estimates (FWB:9UA) - TradingView
NervGen Pharma Corp. Actuals & Estimates (DUS:9UA) - TradingView
NervGen rises as TD Cowen issues new BUY on lead asset - MSN
NervGen Pharma Corp. (NGEN) Q3 2025 Earnings: Slight EPS Beat Highlights Disciplined Expense Management in Pre-Revenue StageFull Year Guidance - dars.gov.et
Spinal Cord Injury Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates By DelveInsight | StemCyte, NervGen Pharma, VA Office of Research and Development, Kessler Institute for Rehab - Barchart.com
Nervgen Pharma Ord Shs (NGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nervgen Pharma Ord Shs (NGEN) Institutional Confidence - TradingKey
Nervgen Pharma Ord Shs (NGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nervgen Pharma Ord Shs (NGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nervgen Pharma Ord Shs (NGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nervgen Pharma Ord Shs (NGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nervgen Pharma Ord Shs (NGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Spinal Cord Injury Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Nipro Corp, Kringle Pharma, Abbvie, Neuroplast, Mitsubishi Tanabe Pharma America, Kringle Pharma - Barchart.com
Nervgen Pharma Ord Shs (NGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NervGen Pharma Corp. Financial Disclosures & SEC Filings - TradingView
NervGen Pharma (NGEN) Investor Relations, Earnings Summary & Outlook - Quartr
NervGen Pharma (NGEN) Receives Buy Rating from TD Cowen, Shares Rally - GuruFocus
NervGen stock rises as TD Cowen issues new Buy (NGEN:NASDAQ) - Seeking Alpha
NervGen stock initiated at Buy by TD Cowen ahead of phase 3 trial - Investing.com UK
ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market - Streetwise Reports
NervGen Pharma (NGEN) Slips 7.5% as Selling Pressure Mounts: Key Support Levels in FocusWMA Signal - dars.gov.et
NGEN Q3 2025 Earnings: Narrowed Loss Beat Estimates as Pipeline AdvancesSubscription Growth Report - dars.gov.et
California Pharma Co. Tests Breakthrough Cancer Drug, Cuts Death Risk 60% - Streetwise Reports
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
NervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program - TipRanks
United StatesMintz Advises On NervGen Pharma’s $60 Million Public Offering - Mondaq
US Biotech Co. Targets Muscular Dystrophy with First-In-Class Drug - Streetwise Reports
Nervgen’s CONNECT Trial Termination: What It Means for NGEN Investors - TipRanks
Biopharma Company Reveals High-Impact SCI Recovery Gains - Streetwise Reports
NGEN Stock Price and Chart — NASDAQ:NGEN - TradingView
NervGen Pharma Company Profile & Introduction - Moomoo
How one School of Medicine researcher’s legacy offers hope for those with spinal cord injuries - Case Western Reserve University
These stocks have an unusual volume in today's session - ChartMill
NervGen reports positive gait analysis data for NVG-291 trial - grafa.com
NervGen Pharma (NGEN) Reports Promising Gait Analysis Results - GuruFocus
Why Is NervGen Pharma Stock Gaining Tuesday? - Benzinga
NervGen reports positive gait analysis data for NVG-291 trial By Investing.com - Investing.com Australia
Finanzdaten der Nervgen Pharma Corp-Aktie (NGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):